All In MedTech

Device Trial Radar · NCT06247397

Effect of HIgh-flow Therapy in Long-term Oxygen Therapy

Effect of HIgh-flow Therapy in Long-term Oxygen Therapy (HILOT): A Multicenter, Registry-based, Randomized Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 310 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

310

Planned (sponsor's estimate)

Start

Jun 10, 2024

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
Skane University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Uppsala University Hospital; Region Stockholm; Region Örebro County; Blekinge County Council Hospital; Blekinge Institute of Technology; Lund University; Region Östergötland; Vastra Gotaland Region; Region Västerbotten; Landstinget i Värmland; ResMed; Swedish Heart Lung Foundation; The Swedish Research Council
First posted
Feb 7, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).

Conditions

  • Chronic Obstructive Pulmonary Disease Severe
  • Interstitial Lung Disease
  • Chronic Respiratory Failure With Hypoxia

Interventions

  • Added high-flow oxygen therapyDevice

    Added high-flow oxygen therapy using the device Lumis HFT during nighttime and at the patient's discretion daytime, with the usual care (low-flow oxygen therapy) the rest of the time.

  • Standard careOther

    Standard care with low-flow oxygen therapy in accordance with clinical routine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first hospitalization or death from all causesTime frame: 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Heart, Lung and Clinical Physiology, Örebro University Hospital

    Örebro, Sweden · Recruiting

  • Research Unit, Blekinge University of Technology

    Karlskrona, Blekinge County, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.